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INTRODUCTION
Peripheral nerve vasculitis is an important condition which can be diagnostically 
challenging and is one of the principal current indications for nerve and muscle biopsy. 
Previous studies have suggested that  combined nerve and muscle  biopsy produces a 
higher diagnostic yield than nerve biopsy alone in the investigation of vasculitis.
Peripheral nerve vasculitis is a pathological process involving infiltration of and 
injury to the walls of the vasa nervorum by inflammatory cells, 1-2 resulting in secondary 
ischaemia and damage to the nerve trunk. The diagnosis is difficult to make on clinical 
grounds  alone  and  usually  requires  the  biopsy  of  affected  tissue  prior  to  starting 
treatment.  Although  peripheral  nerve  vasculitis  is  rare,  it  remains  one  of  the  most 
important indications for performing a nerve biopsy. 
Peripheral nerve vasculitis can occur either as part of multisystem disorders such 
as polyarteritis nodosa or connective tissue disorders (termed SVN, systemic vasculitic 
neuropathy)1  3–5 or  as  a  disorder  restricted  to  the  peripheral  nervous  system (termed 
NSVN, non-systemic vasculitic neuropathy).6–8 
In both groups, striated muscle as well as peripheral nerve may show pathological 
signs of vasculitis. In 1988, Said and Lacroix reported that up to 45% of patients with 
peripheral  nerve  vasculitis  had  demonstrable  evidence  of  vasculitis  in  the  peroneus 
brevis muscle (PBM) but not in the superficial peroneal nerve (SPN) when both were 
biopsied.4 This group therefore suggested that combined SPN/ PBM biopsy (through a 
common incision) in patients with suspected peripheral nerve vasculitis would increase 
the diagnostic yield, an approach supported by more recent studies.1 9 
Based on these studies it has also become accepted practice in units where the 
sural nerve is the more usual nerve biopsied to biopsy the vastus lateralis muscle as well 
(using a second incision during the same procedure) when vasculitis is being considered. 
In order to determine whether combined nerve (usually sural) and vastus lateralis 
muscle biopsy improved diagnostic yield compared with nerve biopsy alone, I studied 
30 cases of pathologically confirmed peripheral nerve vasculitis seen at our institution 
over a 2 year period.
REVIEW OF LITERATURE
Systemic vasculitis has been classically categorized as a primary disorder, such as 
polyarteritis  nodosa,  Churg-Strauss  syndrome,  and  Wegener  granulomatous,  or  as  a 
secondary process, representing a complication from a connective tissue disorder (eg, 
rheumatoid vasculitis), infection, medication, or malignancy. Peripheral neuropathy is a 
well-recognized consequence of systemic vasculitis due to peripheral nerve infarction 
with Wallerian degeneration. Rarely, neuropathy is the sole manifestation of vasculitis, 
referred to as nonsystemic vasculitic neuropathy (NSVN). These conditions are defined 
pathologically by tissue biopsy demonstrating disruption or  destruction of the vessel 
wall  with  inflammatory  cell  infiltrates.  The  diagnosis  of  vasculitic  neuropathy  is 
straightforward  in  patients  with  an  established  diagnosis  of  systemic  vasculitis  and 
classic  features  of  mononeuritis  multiplex.  Most  patients  have  clinical  features  of  a 
subacute,  progressive,  generalised  but  asymmetric,  painful,  sensorimotor 
polyneuropathy. Laboratory tests often indicate features of systemic inflammation, such 
as an elevated sedimentation rate or positive anti-neutrophil cytoplasmic antibody, and 
electrodiagnostic  evaluation  shows  multiple  mononeuropathies  or  a  confluent, 
asymmetric axonal neuropathy. Nerve and muscle biopsy is necessary to establish the 
diagnosis in most cases. 
Nerve Biopsy
Over the years careful studies have lead to a consensus regarding the usefulness of 
biopsy for the diagnosis of vasculitis with peripheral nerve involvement. It seems that: 
1) Only a percentage of diagnosed patients have a positive nerve biopsy 2) Combined 
Nerve and muscle biopsy adds to the overall diagnostic yield than either alone 3) The 
absence  of  a  positive  tissue  biopsy  does  not  exclude  the  disorder  4)  Biopsy  of 
“symptomatic sites”seems to improve the diagnostic yield. 5) Electromyography (EMG) 
and Nerve Conduction Studies (NCS) help in the selection of the biopsy site and 6) 
whole nerve biopsy more useful than fascicular biopsy.
Electrophysiological studies
The  findings  of  NCS  and  EMG  in  the  vasculidities  with  peripheral  nerve 
involvement  reflect  its  pathology.  The  findings  are  those  of  an  axonal  neuropathy 
involving  both  motor  and  sensory  nerves  at  all  levels.  Studies  are  very  useful 
demonstrating  a  “Mononeuritis  multiplex”  pattern  and  also  a  multi-fascic  temporal 
involvement of the peripheral nerve lesions. Conduction block can be seen from nerve 
ischemia. Asymmetries in the compound action potential of different nerves can also 
substantiate a mononeuritic axonal pattern. 
Causes  of  vasculitic  neuropathy  can  be  classified  on  the  basis  of  size  of  the 
vessels  or  primary  versus  secondary  vasculitis.  A  simple  classification  is  based  on 
systemic vasculitis, causing vasculitic neuropathy with other constitutional symptoms or 
serologic  abnormalities,  versus nonsystemic  vasculitis,  which presents  as  neuropathy 
only.
Systemic vasculitis
Systemic necrotizing vasculitis: These vasculitides classically involve small and 
medium-sized arteries  affecting multiple  organ systems,  including the peripheral  and 
central nervous systems. Polyarteritis nodosa is the most common necrotizing vasculitis, 
with greater than 50% involvement of peripheral nerves. The necrotizing vasculitides 
include the following:
Polyarteritis nodosa
Churg-Strauss syndrome
Wegener granulomatosis
Overlap syndrome
Cryoglobulinemia
Hypersensitivity vasculitis:  These vasculitides classically involve small vessels, 
including capillaries, arterioles, and venules. They rarely cause irreversible dysfunction 
of vital organs and have better prognosis than systemic necrotizing vasculitides. Trigger 
is  usually  endogenous  or  exogenous  antigen  exposure.  Cutaneous  manifestations 
dominate the clinical picture but involvement of other organs and the peripheral nervous 
system also is noted. The hypersensitivity vasculitides include the following:
Henoch-Schönlein purpura
Serum sickness
Infectious vasculitis (eg, HIV, hepatitis B)
Drug-induced vasculitis (eg, cocaine, heroin)
Neoplasm (eg, chronic lymphocytic leukemia)
Cryoglobulinemia
Behçet syndrome
Giant cell  arteritides: These vasculitides classically involve large and medium-
sized vessels. Giant cell formation with mononuclear cell infiltrates is seen frequently. 
Peripheral neuropathy is rare and is seen in less than 15% of patients with temporal 
arteritis. The giant cell arteritides include the following:
Temporal arteritis
Takayasu arteritis
Connective tissue disease: Patients with connective tissue disease can present with 
systemic necrotizing vasculitis or hypersensitivity vasculitis. Rheumatoid arteritis (RA) 
is the connective tissue disease that most often causes vasculitis. Vasculitis develops in 
8-25% of patients with RA, usually 10-15 years after onset of RA. Overall, vasculitic 
neuropathy  occurs  in  40-50%  of  patients  with  systemic  vasculitis.  Systemic  lupus 
erythematous  presents  as  polyneuropathy  in  6-21%  of  patients.  Connective  tissue 
diseases most often associated with vasculitis include the following:
Rheumatoid arteritis
Systemic lupus erythematous
Sjögren syndrome
Systemic sclerosis
Nonsystemic vasculitic neuropathy
Localized  vasculitis  affects  either  the  central  nervous  system (primary  central 
nervous  system  angiitis)  or  the  peripheral  nervous  system.  Nonsystemic  vasculitic 
neuropathy involves small and medium-sized arteries.
Clinical and histologic presentation is similar to that of neuropathy observed in 
systemic vasculitis but without any other organ involvement.
Nonsystemic  vasculitic  neuropathy  represents  one  third  of  all  vasculitic 
neuropathies. Prognosis is better than that of systemic vasculitic neuropathy.
Paraneoplastic  vasculitic  neuropathy:  Paraneoplastic  vasculitic  neuropathy  is  a 
rare  paraneoplastic  syndrome  characterized  by  nonsystemic  subacute  vasculitic 
neuropathy.  The  cancers  most  commonly  associated  with  paraneoplastic  vasculitic 
neuropathy are small cell lung cancer and lymphomas.
Laboratory Studies
Laboratory  studies  are  more  helpful  in  systemic  than  nonsystemic  vasculitis; 
however, obtain the following studies in any patient in whom vasculitic neuropathy is 
suspected. In general, place the results in the context of the clinical presentation for a 
diagnosis. For those individuals with multiple high levels of the inflammatory markers 
listed here, consultation with a rheumatologist is strongly recommended.
Nonsystemic vasculitic neuropathy has a better prognosis than systemic vasculitic 
neuropathy. The former may have normal laboratory results, while systemic vasculitis 
often features elevated antinuclear antibody (ANA) titers, erythrocyte sedimentation rate 
(ESR), and other more specific markers of disease.
ESR (high, after age adjusted) - More than 70% of patients show ESR >20 mm/h
Antinuclear antibody titer (high in systemic diseases associated with vasculitic 
neuropathy)
Extractable nuclear antigens, p-ANCA and c-ANCA
Rheumatoid factor
Antineutrophil cytoplasmic antibodies
Hepatic enzymes
Renal function tests
Serum complement
Serum  immunoelectrophoresis  (or  immunofixation)  and  quantitative 
immunoglobulins
Cryoglobulins
Hepatitis B antigen and antibody
Hepatitis C antigen
Routine cell count and serum electrolytes are indicated. Anemia is present in up to 
30% of patients.
Serum analysis for other common causes of neuropathy, including hemoglobin 
A1c (HbA1c) and fasting glucose to rule out diabetes, thyroid function tests, B-12 and 
folate, and rapid plasma reagent (RPR).
CSF analysis can show high protein levels (>50 mg) in a small  percentage of 
patients.
Imaging Studies
Brain imaging studies are usually not necessary, and a central nervous system 
etiology can be excluded comfortably by an accurate neurologic examination.
Magnetic resonance imaging (MRI) of the spine can be helpful in excluding a 
spinal nerve root lesion when suggested.
Other Tests
Nerve  conduction  studies  and  electromyography  Electrodiagnostic  testing  is 
essential in making the diagnosis of any neuropathy, especially in vasculitic neuropathy. 
Electrodiagnostic testing can help accurately define the pathophysiology and localize the 
extent and distribution of the neuropathy. It also can provide information on whether the 
disease is active in the form of signs of active denervation, which accordingly facilitates 
choice of treatment protocol.
The  predominant  electrophysiologic  feature  of  vasculitic  mononeuropathy 
multiplex is axonal loss. "Conduction block" in vasculitic mononeuropathy multiplex is 
secondary to focal axonal conduction failure, presumably related to infarct of the axon.
Needle  electromyography  can  demonstrate  denervation  potentials.  Presence  of 
positive sharp waves and fibrillation potentials indicates active denervation. Amplitude 
and  duration  of  motor  units  assess  the  duration  of  axon  loss  and  the  presence  of 
reinnervation changes. Recruitment pattern identifies the amount of functional axonal 
loss.
Collins MP et al; 10 in a study titled Nonsystemic Vasculitic Neuropathy: Update 
on  Diagnosis,  Classification,  Pathogenesis,  and Treatment  has  said  that  the  primary 
systemic  vasculitides  are  autoimmune  disorders  characterized  by  chronic  immune 
responses directed against vascular structures. They commonly affect small or medium-
sized vessels in the peripheral nervous system (PNS), producing vasculitic neuropathies. 
Some patients develop vasculitis clinically restricted to the PNS, known as nonsystemic 
vasculitic neuropathy (NSVN), the most commonly encountered vasculitic neuropathy 
in pathologically based series. Diabetic and nondiabetic radiculoplexus neuropathies are 
clinical variants of NSVN. NSVN is clinically similar to systemic vasculitis-associated 
neuropathies  except  for  reduced  severity.  Patients  most  commonly  present  with 
progressive, stepwise pain, weakness, and numbness over multiple months. Almost all 
exhibit  a  multifocal  or  asymmetric,  distally  accentuated pattern of  involvement.  The 
most commonly affected nerves are the common peroneal nerve in the leg and the ulnar 
nerve in the arm. Sedimentation rate is mildly to moderately elevated in 50%; other 
markers of systemic inflammation are generally normal. Electrodiagnostic studies reveal 
a  predominantly  axonal,  asymmetric,  sensorimotor  polyneuropathy,  but  pseudo-
conduction blocks may occur. Definite diagnosis requires biopsy evidence of vascular 
inflammation and signs of active or remote vascular damage. In biopsies lacking definite 
vasculitis,  the  diagnosis  is  suspected  if  axonal  alterations  are  accompanied  by 
perivascular inflammation and such supportive features as Wallerian-like degeneration, 
asymmetric  fiber  loss,  hemosiderin,  vascular  immune  deposits,  neovascularization, 
myofiber necrosis/regeneration, focal perineurial damage, and endoneurial purpura. 
In Approach to vasculitic neuropathies, Lacomis D, et al;11  says since vasculitic 
neuropathy  is  treatable  and  potentially  debilitating,  clinicians  should  develop  an 
approach to neuropathy that increases the likelihood of uncovering existing systemic or 
nonsystemic vasculitis. The presence of a connective tissue disease, systemic vasculitis, 
asymmetric  or  non--length-dependent  axonal  polyneuropathy,  or  multiple  axonal 
mononeuropathies should heighten suspicion, but vasculitic neuropathy can also present 
as  a  distal  symmetric  polyneuropathy  with  or  without  other  organ  involvement. 
Electrodiagnostic  testing  utilizing  extensive  nerve  conductions  may  be  helpful  in 
identifying features suggestive of vasculitic neuropathy and in selecting an abnormal 
nerve and muscle for  biopsy confirmation.  An array of  laboratory tests may lead to 
identification of a systemic disorder  that  is  either characterized by or  predisposes to 
vasculitic neuropathy. 
Burns TM, et al;12 reviewed the classification of vasculitis and the clinical features 
of  vasculitic  neuropathy.  Vasculitic  neuropathy  usually  presents  with  painful 
mononeuropathies  or  an  asymmetric  polyneuropathy  of  acute  or  subacute  onset. 
Neurologists should categorize vasculitic neuropathy in terms of clinical features (eg, 
systemic  or  non systemic)  and in  terms  of  histopathology  (eg,  nerve  large  arteriole 
vasculitis or nerve microvasculitis). Systemic vasculitis should be classified further into 
one of the primary and secondary forms. 
Gorson  KC13 in   an  update  on   Vasculitic  neuropathies  has  stated  that   the 
diagnosis  of  vasculitic  neuropathy  is  straightforward  in  patients  with  an  established 
diagnosis of systemic vasculitis and classic features of mononeuritis multiplex. Most 
patients have clinical features of a subacute, progressive, generalized but asymmetric, 
painful,  sensorimotor  polyneuropathy.  Laboratory  tests  often  indicate  features  of 
systemic  inflammation,  such  as  an  elevated  sedimentation  rate  or  positive  anti-
neutrophil  cytoplasmic  antibody,  and  electrodiagnostic  evaluation  shows  multiple 
mononeuropathies  or  a  confluent,  asymmetric  axonal  neuropathy.  Nerve  biopsy  is 
necessary to establish the diagnosis in most cases, particularly in patients with NSVN.
Schweikert K et al;14 in Contribution of nerve biopsy to unclassified neuropathy 
has determined the etiology of the neuropathies  in 14 patients (37%), i.e. in 15% of 
chronic symmetric, 30% of chronic asymmetric, 50% of subacute symmetric and 62.5% 
of subacute asymmetric neuropathies. The biopsy was diagnostic in 6 patients (16%), 
where it  showed a vasculitis,  and supportive in 8 patients (21%). He concluded that 
contribution of nerve biopsy to the diagnosis of peripheral neuropathy was highest in 
acute and subacute asymmetric forms of neuropathy and lowest in chronic symmetric 
forms.  The  main  indication  for  nerve  biopsy  remains  the  diagnosis  of  vasculitic 
neuropathy, a potentially treatable disorder.
Vital  C  et  al;15 reviewed  202  biopsies  performed  on  patients  with  suspected 
vasculitic  neuropathy,  of  which  24  Churg-Strauss  cases  are  studied  separately. 
Specimens from the superficial peroneal nerve and peroneus brevis muscle were taken 
simultaneously  by  one  incision.  Without  taking  into  account  constitutional  signs, 
systemic  involvement  was  present  in  131  patients,  whereas  the  remaining  47 
corresponded to non-systemic patients with lesions limited to peripheral nervous system 
and adjoining muscles.  Diagnosis  of  panarteritis  nodosa  or  microscopic  polyangiitis, 
according to the size of involved vessels, was attested by an infiltration of vessel walls 
by inflammatory cells associated with fibrinoid necrosis or  sclerosis.  Microvasculitis 
was diagnosed when inflammatory infiltration concerned small vessels with few or no 
smooth-muscle fibers and without any necrosis. Microvasculitis was present in 11 of 46 
non-systemic  cases,  and  this  predominance  is  statistically  significant.  Isolated 
perivascular  cell  infiltrates  in  the  epineurium  were  considered  not  significant  but 
allowed  the  diagnosis  of  'probable  vasculitis'  if  associated  with  at  least  one  of  the 
following features: regenerating small vessels, endoneurial purpura, asymmetric nerve 
fiber  loss,  and/or  asymmetric  acute  axonal  degeneration.  Necrotizing  vasculitis  was 
visible  in  60 cases:  in  nerve (16  cases),  in  muscle  (19 cases),  and both (25  cases). 
Microvasculitis was present in 25 cases: in nerve (19 cases), muscle (four cases), or both 
(two cases). Moreover, granulomatous vasculitis was found in the nerve of one non-
systemic patient presenting also sarcoid granulomas in muscle. There were 24 'probable 
vasculitis' and 68 negative cases. Muscle biopsy improved the yield of definite vasculitis 
by 27%.
Collins  MP,  Periquet  MI;  6  in  a  study on Isolated  vasculitis  of  the  peripheral 
nervous system  has stated that Vasculitis restricted to the peripheral nervous system 
(PNS), referred to as nonsystemic vasculitic neuropathy (NSVN), has been described in 
many reports since 1985 but remains a poorly understood and perhaps under-recognized 
condition. There are no uniform diagnostic criteria. Classification is complicated by the 
occurrence of vasculitic neuropathies in many systemic vasculitides affecting small-to-
medium-sized vessels and such clinical variants as nonsystemic skin/nerve vasculitis and 
diabetic/non-diabetic lumbosacral radiculoplexus neuropathy. Most patients present with 
painful,  stepwise  progressive,  distal-predominant,  asymmetric  or  multifocal,  sensory-
motor deficits evolving over months-to-years. NSVN is identical to but less severe than 
systemic  vasculitis-associated  neuropathies  (SVNs).  All  vasculitic  neuropathies  are 
axonal  by  electrodiagnostic/pathologic  criteria.  Laboratory  testing  is  unremarkable 
except for mildly elevated erythrocyte sedimentation rate (ESR) in 50%. Highly elevated 
ESRs,  leukocytosis,  rheumatoid  factors,  and  anti-neutrophil  cytoplasmic  antibodies 
(ANCAs)  raise  concern  for  underlying  systemic  vasculitis.  Without  a  specific 
clinical/laboratory  marker,  the  condition  depends  on  nerve  biopsy  for  diagnosis. 
Biopsies showing necrotizing vasculitis are about 50% sensitive, mandating reliance on 
"suspicious"  changes  in  many  patients.  Vasculitic  lesions  predominate  in  smaller 
epineurial vessels and are milder than those in SVNs. The disorder is often accompanied 
by subclinical involvement of adjacent muscles and skin. NSVN has the potential to 
spontaneously  relapse  and  remit  but  neurologic  deficits  accumulate.  No  randomized 
controlled  trials  have  been  performed,  but  one  retrospective  cohort  survey  showed 
combination therapy to be more effective than prednisone alone. Although most patients 
have  a  good  outcome,  more  than  30%  relapse  and  60% have  residual  pain.  Many 
nosologic, pathogenic, diagnostic, and therapeutic questions remain unanswered.
Collins MP, Periquet MI;16 in Non-systemic vasculitic neuropathy reviewed the 
literature  on  non-systemic  vasculitic  neuropathy,  with  emphasis  on  recent  advances, 
summarizing the clinical presentation, diagnosis, pathology, treatment, and outcome of 
this  condition,  and  speculating  on  its  nosological  status  vis-à-vis  the  systemic 
vasculitides. Analysis of the clinical characteristics of this cohort demonstrated a higher 
incidence  of  painful,  asymmetric,  overlapping  deficits  than  in  previous  studies. 
Extended  follow-up revealed  a  high  relapse  rate,  low risk  of  systemic  spread,  high 
incidence of chronic pain, relatively good neurological outcome, and low mortality rate. 
Analysis  of  therapeutic responses showed better  outcomes with combination therapy 
than corticosteroid monotherapy. Another recent  report proposed a role for magnetic 
resonance  angiography  in  the  diagnosis  and  follow-up  of  non-systemic  vasculitic 
neuropathy.  Recent  pathological  studies  implicated  proinflammatory  cytokines  and 
matrix  metalloproteinase-9  in  the  mediation  of  vascular  and axonal  damage in  non-
systemic  vasculitic  neuropathy.  Non-systemic  vasculitic  neuropathy  is  one  of  many 
localized  vasculitides,  with  involvement  restricted  to  nerves  and (possibly)  muscles. 
Inclusion and exclusion criteria  differ  between reported cohorts.  All  require  a  nerve 
biopsy  diagnostic  of  or  suspicious  for  vasculitis  and  no  extra-neuromuscular 
involvement.  Patients  typically  present  subacutely  with  a  painful, 
multifocal/asymmetric,  distal-predominant  neuropathy.  In  the  absence  of  clinical  or 
laboratory evidence of systemic vasculitis or a condition predisposing to such, prognosis 
with treatment is good. Pathological data are supportive of a primary T-cell-mediated 
immunopathogenesis.  Some  patients  classified  as  having  non-systemic  vasculitic 
neuropathy have a systemic vasculitis presenting with neuropathy; in others, the disease 
is organ-specific.
Said G, Lacroix C.;2 in a study on Primary and secondary vasculitic neuropathy 
reported that focal and multifocal neuropathy occur as a consequence of destruction of 
the arterial wall and occlusion of the lumen of small epineurial arteries. Vasculitis may 
also complicate the course of other conditions ranging from infection with the HIV and 
with  the  B  and  C  hepatitis  viruses  to  diabetes  and  sarcoidosis.  Pathologically 
polymorphonuclear  cells  are  present  in  the  infiltrates  of  the  vessel  wall  in  primary 
necrotizing vasculitis, while in secondary vasculitis the inflammatory infiltrate is mainly 
composed  of  mononuclear  cells.  In  all  instances  symptomatic  vasculitis  requires 
corticosteroid to control the inflammatory process and prevent further ischemic nerve 
lesions.
Pagnoux C, Guillevin L.;17 in Peripheral neuropathy in systemic vasculitides has 
found  that   Vasculitic  neuropathy  may  result  from  primary  or  secondary  systemic 
vasculitides, or may be restricted to the PNS, in a form that is now also considered to be 
a  systemic  vasculitis.  The  blood-nerve  barrier  is  not  as  efficient  as  the  blood-brain 
barrier.  Inflammatory  cell  infiltration  into  the  vasa  nervorum and epineurial  arteries 
leads to ischemic axonal nerve injury and is facilitated by additional breaches in the 
blood-nerve  barrier,  induced  by  proinflammatory  cytokines,  oxidative  stress-derived 
molecules, and matrix metalloproteinases. Although animal models of myeloperoxidase 
or, now, proteinase 3-antineutrophil cytoplasmic autoantibody-inducing vasculitis have 
been developed, they do not support a role for antineutrophil cytoplasmic autoantibodies 
in PNS involvement. Treatment should be chosen based on the other organ involvement 
and the patient's general condition. When PNS involvement is isolated, corticosteroids 
alone should be used as first-line treatment. Apart from the so-called nonsystemic nerve 
vasculitis,  PNS  involvement  is  rarely  the  sole  clinical  sign  of  systemic  necrotizing 
vasculitis, and its association with other typical manifestations is often suggestive of the 
diagnosis of vasculitis. Herein are summarized recent advances that have clarified but 
not  yet  fully  elucidated  the  pathogenesis  of  peripheral  neuropathy  in  systemic 
vasculitides, together with the latest clinical findings and therapeutic strategies. 
Seo JH, Ryan HF, Claussen GC, Thomas TD, Oh SJ; 18 in Sensory neuropathy in 
vasculitis:  a  clinical,  pathologic,  and electrophysiologic  study  presented  the  clinical, 
pathologic, and electrophysiologic features of 17 (16%) cases of sensory neuropathy in 
vasculitis (SNV) among 106 cases with histologically proven vasculitic neuropathy that 
were collected over the last  30 years.  In 41% of cases, SNV was found as systemic 
vasculitic neuropathy in association with primary vasculitic disease. The most common 
clinical presentation was symmetric polyneuropathy, seen in 53% of cases. The most 
common  nerve  conduction  pattern  was  diffuse  neuropathy  pattern  of  axonal 
degeneration. Sural nerve biopsy was diagnostic in 88% of cases. In two cases, muscle 
biopsy  was  necessary  for  the  definite  diagnosis  of  vasculitis.  Non-systemic  SNV is 
usually benign. Of 11 patients followed for longer than 2 years, none developed motor 
weakness due to neuropathy. Sensory neuropathy, regardless of symmetry, can be due to 
vasculitis.
Vrancken AF, Notermans NC, Jansen GH, Wokke JH, Said G;  19 in Progressive 
idiopathic axonal neuropathy--a comparative clinical and histopathological study with 
vasculitic neuropathy evaluated whether progressive idiopathic axonal neuropathy could 
be a pathologically difficult  to prove vasculitic neuropathy pathologically difficult  to 
prove or  if  it  could be a separate  clinical  entity  (i.  e.  with the axon as the primary 
immunological target), we performed a comparative clinical and histopathological study 
in 10 patients with progressive idiopathic axonal neuropathy, 10 patients with vasculitic 
neuropathy, and 12 patients with chronic idiopathic axonal polyneuropathy (CIAP). The 
clinical  features  and  disease  course  in  patients  with  progressive  idiopathic  axonal 
neuropathy  and  patients  with  vasculitic  neuropathy  were  similar.  Six  patients  with 
progressive  idiopathic  axonal  neuropathy  had  been  treated  with  prednisone  and/or 
intravenous immunoglobulin. Disability decreased in all these six patients, but also in 
two of the four non-treated patients. Upon reviewing the sural nerve biopsy specimens, 
vasculitis  was  found  in  one  patient  with  progressive  idiopathic  axonal  neuropathy. 
Vasculitis-associated  signs  of  ischemic  injury  or  inflammation  (most  notably:  large 
variation in fascicular axonal degeneration, perivascular inflammation, inflammation of 
the  blood  vessel  wall  without  lumen  obstruction)  were  found  in  four  patients  with 
progressive idiopathic axonal neuropathy, in all patients with vasculitic neuropathy, but 
were absent in patients with CIAP. The findings show that there is a small chance of 
finding  sural  nerve  vasculitis  upon  scrutinising  biopsy  examination  in  progressive 
idiopathic axonal neuropathy. The presence of vasculitis-associated signs in progressive 
idiopathic axonal neuropathy suggests that some of these patients could have vasculitic 
neuropathy, even if vasculitic lesions cannot be demonstrated. However, if inflammatory 
changes cannot be demonstrated this does not preclude an immune-mediated origin.
Carolei A, Sacco S; 20 in Central nervous system vasculitis states that vasculitis is 
an inflammation of the vessel  wall.  It  may be either  primary or  secondary.  Primary 
vasculitis includes systemic vasculitis (large, medium, and small-vessel vasculitis) and 
localized vasculitis  (isolated angiitis  of the central nervous system and non-systemic 
vasculitic  neuropathy).  Secondary  vasculitis  may  be  present  in  connective  tissue 
disorders  or  may  be  caused by infections,  neoplasms,  and substance  abuse.  Patients 
presenting with symptoms suggestive of vasculitis require brain neuroimaging, lumbar 
puncture, and angiography, but only biopsy allows a definite diagnosis. 
Heuss D, Schlotter-Weigel B, Sommer C;21 in Diagnosis and therapy of vasculitic
neuropathy.  Consensus statement  of  the German Centers  for  Neuromuscular  Disease 
distinguished  neuropathies associated with primary and secondary systemic vasculitis, 
with rheumatic diseases, with malignant disorders, drug-induced vasculitis and the non-
systemic  vasculitic  neuropathies  (NSVN).  The  typical  clinical  picture  consists  in  an 
asymmetric or multifocal, painful sensorimotor neuropathy with an acute, subacute or 
chronic  course  and  acute  relapses.  Neurophysiology  reveals  an  active,  asymmetric, 
axonal sensorimotor neuropathy. The disorders usually respond to immunosuppressive 
treatment. A diagnosis of definite vasculitis can be made with evidence of vasculitis in a 
biopsy specimen. The absence of positive morphological evidence, however, does not 
exclude  the  diagnosis.  There  is  no  single  laboratory  test  that  can  prove  or  exclude 
vasculitis, in NSVN even an elaborate panel of blood tests can show normal findings. 
Systemic vasculitis has an incidence of 4/100,000 per year and, untreated, has a poor 
prognosis, which is greatly improved by the use of immunosuppressive treatment. The 
prognosis  of  NSVN  is  generally  better,  although  many  patients  need  long  term 
immunosuppression. Current treatment recommendations for vasculitic neuropathies are 
presented.
Griffin JW;  22 in his study on Vasculitic neuropathies has stated that vasculitis 
typically  affects  the  50-  to  400-micron  vessels  of  the  vasa  nervorum,  leading  to 
randomly distributed ischemia along the course of the nerve. This, in turn, leads to a 
distinctive picture,  multiple mononeuropathy,  as  a frequent but  not  invariant  clinical 
consequence of vasculitis. The diagnosis of vasculitic neuropathy is usually made by 
biopsy  histologic  confirmation.  The  response  to  treatment  varies  among  different 
vasculitides;  vasculitis  restricted to the peripheral  nervous system is often especially 
responsive.
Said G.;23 in his study on Vasculitic neuropathy states that the pathogenesis of 
primary vasculitides, which are assumed to have an autoimmune pathogenesis, is not 
well understood. The endothelial cell adhesion molecules seem to play an active role, 
which  varies  according to  the histopathologic  stage  of  vascular  lesions.  The  role  of 
genetic  factors  also  seems  quite  important,  at  least  in  an  experimental  model.  The 
reliability of antineutrophil cytoplasmic antibodies testing in diagnosis and follow-up of 
patients with vasculitis is reviewed. The conclusion is that antineutrophil cytoplasmic 
antibodies status can be a very useful diagnostic adjunct to the evaluation of patients 
with suspected Wegener's granulomatosis, but is not a substitute for clinical expertise 
and histopathologic data during the course of providing patient care. The neurological 
manifestations of Churg-Strauss syndrome (a variant of polyarteritis nodosa) are very 
similar  to  those  that  occur  in  polyarteritis  nodosa.  A  role  for  vasculitis  has  been 
confirmed  in  proximal  diabetic  neuropathy,  which  may  pave  the  way  for  new 
therapeutic developments.
Olney  RK;24 in  his  study  on  Neuropathies  associated  with  connective  tissue 
disease reported that  neuropathies are a common neurologic manifestation of diffuse 
connective  tissue  disease.  Vasculitic  neuropathy  requires  prompt  diagnosis  and 
treatment to improve its outcome. It is commonly multifocal but may be confluent and 
symmetrical. Vasculitic neuropathy needs to be distinguished from the more common 
syndromes of compression neuropathy, which may also be multifocal, and nonvasculitic 
distal axonal polyneuropathy. Sensory neuronopathy is a distinctive syndrome unique to 
Sjögren's  syndrome  among  the  connective  tissue  diseases.  Trigeminal  sensory 
neuropathy may be the presenting feature of systemic sclerosis or may develop during 
the  course  of  other  connective  tissue  diseases.  This  article  reviews  the  clinical  and 
diagnostic  features  of  neuropathies  associated  with  the  common  diffuse  connective 
tissue diseases.
Davies  L.;  25 in  his  study  on  Vasculitic  neuropathy  stated  that  patients  with 
vasculitic neuropathy may present with either mononeuritis multiplex, or a symmetrical 
or asymmetrical sensorimotor neuropathy. In those patients whose neuropathy is part of 
a systemic vasculitis the neuropathy can be expected to improve leaving only mild or 
moderate functional disability. Nevertheless, the long-term outlook for such patients is 
poor  with  a  5-year  survival  of  around  50%  with  most  excess  deaths  being  due  to 
vascular  disease.  The  prognosis  in  non-systemic  vasculitic  neuropathy  is  almost 
certainly substantially  better  than this.  Treatment  of  vasculitic  neuropathy should be 
based  on  diagnosis  by  tissue  biopsy,  usually  of  nerve,  and  early  use  of  aggressive 
immunosuppression.
Kissel JT, Mendell JR;26 in a study on Vasculitic neuropathy states that peripheral 
neuropathy is common in many vasculitic syndromes and may be the only manifestation 
of the underlying vasculitic disease. Although traditional teaching has been that a true 
multiple mononeuropathy is the classic clinical presentation of vasculitic neuropathy, an 
overlapping  (or  extensive)  multiple  mononeuropathy  or  a  distal  symmetric 
polyneuropathy is commonly encountered. Similarly, the leukocytoclastic reaction has 
traditionally been considered the primary mechanism of vessel injury in these diseases, 
although more recent evidence suggests that cellular-mediated mechanisms may be more 
important  in  peripheral  nerve.  In  this  review,  new concepts  concerning  the  clinical 
presentation,  pathogenesis,  diagnosis,  and  treatment  of  vasculitic  neuropathy  are 
discussed, particularly in relation to the syndrome of isolated peripheral nerve vasculitis. 
Oh SJ;27 in Diagnostic usefulness and limitations of the sural nerve biopsy reviews 
the diagnostic usefulness and limitations of this procedure. Based on 385 sural nerve 
biopsies, we found clinically helpful or relevant information in 45% of cases. In 24% of 
cases, specific diagnoses were obtained, among which vasculitic neuropathy was most 
common.             
                           
OBJECTIVE
1. To correlate the clinico-pathologic, and electrophysiologic features of 30 cases of 
vasculitic neuropathy 
2. To determine whether combined nerve (usually the sural) and muscle (usually the 
vastus lateralis) biopsy improved diagnostic yield compared with nerve biopsy 
alone.
MATERIALS AND METHODS
The study group comprised of  all patients admitted to the Dept. of  Neurology 
Govt   Stanley  Hospital   between   Jan  2007-Dec  2008  with  a  clinical  diagnosis  of 
vasculitic neuropathy, confirmed histopathologically  with nerve and muscle biopsies.
The nerve biopsies were  taken from the sural nerve  and muscle  biopsy  was 
taken  taken from the vastus lateralis muscle.  
The  biopsy  specimens  were  sent  IN  2%  CIDEX  SOLUTION  to  Dept.  of 
Neuropathology,  NIMHANS,  Bangalore  for  tissue  processing  and  histpathologic 
examination
Pathological selection criteria
Nerve biopsies were classified as showing definite or probable vasculitis. Definite 
vasculitis was diagnosed if endoneurial or epineurial vessels showed evidence of vessel 
wall  infarction  in  association  with  perivascular  or  transmural  infiltration  by 
inflammatory  cells.  Vessel  wall  infarction  was  diagnosed  if  there  was  evidence  of 
destruction and disorganisation of  the muscularis by fibrinoid necrosis, disruption of the 
endothelium or internal elastic lamina, thrombosis of the lumen or haemorrhage into the 
wall  of  the  vessel.  Probable  vasculitis  was  diagnosed  if  there  was  transmural  or 
perivascular inflammation not accompanied by vessel wall infarction.
In muscle biopsy specimens, similar diagnostic criteria for definite vasculitis were 
applied.  Probable  vasculitis  was  diagnosed  where  transmural  inflammation  was  not 
accompanied  by  fibrinoid  necrosis  of  the  vessel  wall  or  any  of  the  other  vascular 
changes  described  above  as  representing  evidence  of  definite  vasculitis.  In  muscle, 
transmural inflammation alone without the additional features which were applied to 
nerve biopsies were sufficient to diagnose probable vasculitis.
Clinical and electrophysiological data
Clinical  features were studied to provide clinical and electrophysiological data 
for  all  patients  meeting  the  pathological  criteria  for  vasculitis.  All  patients  were 
clinically suspected of having vasculitis. The pattern of neuropathy was determined by 
the findings on clinical examination. Nerve conduction studies and electromyography 
were performed, using standard techniques. 
Patients  with  pathologically  confirmed  vasculitis  were  divided  into  SVN and 
NSVN groups. The criteria that were used to define cases as NSVN were as follows: (1) 
no  evidence  of  involvement  outside  the  peripheral  nervous  system  (except  striated 
muscle)  and  (2)  no  underlying  causative  agent  (hepatitis  B,  hepatitis  C,  HIV,  drug 
exposure, connective tissue disorder, malignancy ). Patients with diabetes mellitus were 
not  excluded.  Systemic  vasculitis  was  defined  as  in  the  Chapel  Hill  Consensus 
Conference. Constitutional symptoms such as fever and weight loss and serological tests 
such as antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), 
erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) were not in themselves 
used  to  diagnose  SVN  unless  independent  clinical  criteria  for  the  diagnosis  of  a 
connective tissue disorder were present. 
Statistics  were  performed  using  SigmaStat  3.5  software.  Categorical  variables 
were analysed using the 2, Fisher’s exact test or McNemar’s test where appropriate. The 
Mann–Whitney rank sum test was used to compare the duration of symptoms prior to 
biopsy in SVN and NSVN cohorts as the data were not normally distributed. 
RESULTS
Clinical features
Thirty   patients  were  identified  on  the  basis  of  a  pathologically  confirmed 
diagnosis  of  vasculitis  between  Jan  2007  and   Dec  2008.  58% had  SVN and  42% 
NSVN. There was a female preponderance (women:men 19:11). Age range at the time 
of biopsy was 18–68 years (mean 47 (SD 13)). The clinical features were more severe in 
the older cohort. Duration of symptoms prior to biopsy ranged from 1 to 40 months 
(mean 15 (SD 23), median 6). Mean duration of symptoms prior to biopsy was shorter in 
the SVN than in the NSVN group (8.5 vs 23.5 months, respectively) but this difference 
was not statistically significant (Mann–Whitney rank sum test p = 0.36). The majority 
(87%) of neuropathies were painful on presentation and the most common presentation 
was with either an asymmetric sensorimotor neuropathy or mononeuritis multiplex (45% 
and  20% of  patients,  respectively).  17% had  only  sensory  findings  on  presentation. 
There was a distal predominance. Electrophysiologically the most commonly involved 
nerve  was  the  peroneal  (86%  of  patients);  in  the  upper  limbs  the  most  commonly 
involved nerve was the ulnar (63% of patients). 
In the NSVN group, 16% of patients suffered weight loss and 5% had fever. As 
expected,  systemic  features  were  much  commoner  in  the  SVN  group  (p<0.001, 
comparing  the  proportion  of  patients  with  systemic  symptoms  SVN  versus  NSVN; 
Fisher’s exact test), in which weight loss occurred in 52% and fever in 18%. In the SVN 
group there were a number  of  additional  features,  including:   fever(26%),  arthralgia 
(23%), malaise(19%), 
Laboratory findings
Patients  with  SVN compared  with  those  with  NSVN were  significantly  more 
anaemic (p = 0.004, Fisher’s exact test) had a raised ESR (p = 0.01, 2 test) and had a 
positive serology for ANCA (p = 0.003, Fisher’s exact test). A greater proportion of 
patients  with SVN had positive ANA and RF serology compared with patients  with 
NSVN but these differences did not reach significance. 
Neurophysiology
The most frequent finding was that of an asymmetric or patchy axonal motor and 
sensory  peripheral  neuropathy  (43%).  Relatively  infrequent  mononeuropathies  were 
identified (8%). Some patients were reported to have had a symmetrical or generalised 
neuropathy ( 25%). Occasional borderline motor slowing was identified but rarely in the 
frankly demyelinating range (less than 38 m/s in the upper limbs). In all cases of marked 
motor slowing there was evidence of significant or severe loss of motor axons. There 
were no cases with convincing findings of demyelination and no cases of partial motor 
conduction block. 17% of patients  had a principally sensory neuropathy. 
Pathological findings
In 36% of patients the nerve biopsy demonstrated definite and in 62% of patients 
probable vasculitis.  In patients with SVN the nerve biopsy was more likely to show 
definite (as opposed to probable) vasculitis when compared with NSVN patients (48% 
vs 18%, p = 0.04, Fisher’s exact test). The muscle biopsy demonstrated vasculitis in 
48% of the vastus lateralis  biopsies;  13% muscle biopsies showed definite and 35% 
probable vasculitis. None of the muscle biopsies demonstrating probable vasculitis had 
accompanying signs of remote vascular injury. Of those muscle biopsies which did not 
demonstrate  vasculitis,  five  showed  an  inflammatory  cell  infiltrate.  21  %  muscle 
biopsies showed myofibre necrosis and 63 % showed neurogenic changes.
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DISCUSSION
The  demographic  features  of  our  vasculitis  cohort  were  similar  to  previous 
studies, showing a female predominance and a tendency for the condition to affect the 
elderly.5, 7, 11–14 In agreement with previous reports,3 ,6, 7, 15, 16 we have found that pain is a 
prominent symptom described by the vast majority (87%) of our patients. Most of our 
patients  presented  with  an  asymmetric  neuropathy,  usually  either  an  asymmetric 
sensorimotor neuropathy (45%) or mononeuritis multiplex (20%). Only 11% presented 
with  a  symmetrical  sensorimotor  neuropathy.  Reports  of  the  proportion  of  patients 
presenting with symmetrical compared with asymmetric findings in the literature vary 
greatly from 2% of patients having a symmetrical neuropathy in one recent study of 
NSVN6 up  to  76%17 in  a  study  involving  patients  with  SVN  and  NSVN.  These 
discrepancies may relate to the extent to which minor asymmetries on examination are 
taken into account, or to the different patient populations. No patient in our cohort had a 
purely motor neuropathy although 15% presented with a pure sensory neuropathy, a 
proportion similar to previous reports.6, 7, 9, 12, 18,  The most commonly involved nerve in 
the lower limbs was the peroneal nerve and in the upper limbs the ulnar nerve. The 
frequent involvement of the peroneal nerve is compatible with experimental evidence 
demonstrating that the sciatic nerve bifurcation is a watershed zone, being particularly 
susceptible to ischaemia.20 
Peripheral  nerve  vasculitis  can  occur  either  as  part  of  a  multisystem disorder 
(SVN) or  as  a  disorder  restricted  to  the  peripheral  nervous  system (NSVN).  In  our 
cohort,  patients with SVN had a shorter duration between symptom onset and nerve 
biopsy, and were more likely to have anaemia, raised inflammatory markers and positive 
serology for ANA, ANCA or RF than patients with NSVN. 
It can be difficult to compare published cohorts of peripheral nerve vasculitis as 
different  definitions  of  vasculitis  have  been  used.  In  this  study,  we  categorised 
peripheral  nerve  vasculitis  into  definite  and probable.  In  definite  vasculitis,  there  is 
evidence of both vascular inflammation as well as recent damage to the vessel wall. In 
probable  vasculitis,  there  are  transmural  or  perivascular  inflammatory  cells  in 
combination with other features suggestive of vasculitis. A number of previous series 
have also subdivided cases into definite and probable vasculitis6, 7 while some have been 
more restrictive by including only those cases in which there is evidence of both vessel 
wall  inflammation  and  necrosis.4 The  inclusion  of  cases  in  which  the  nerve  biopsy 
shows  evidence  of  vessel  wall  inflammation  without  frank  necrosis  but  with  other 
features suspicious of vasculitis (ie, asymmetric nerve fibre loss, prominent Wallerian 
degeneration, predominant axonal changes) has been shown to increase the estimated 
sensitivity of the procedure from 61% to 86% with only a small loss of specificity.12 
It  was  first  reported  in  1988  that  combined  nerve  and  muscle  biopsy  using 
superficial peroneal nerve (SPN) and peroneus brevis muscle (PBM) could increase the 
diagnostic yield compared with nerve biopsy alone. In a more recent review, the same 
authors described a larger cohort of 425 patients in which vasculitic lesions were found 
in muscle only in 28% of patients, nerve only in 45% and both in 31.5% of patients.1 A 
number  of  other  groups9  ,  12  ,   21 describing  combined  SPN and  PBM biopsy  in  the 
diagnosis  of  vasculitis  have  also  found  a  sizeable  percentage  of  patients  in  whom 
vasculitis is present in muscle but not nerve (varying between 9% and 27%). There are 
fewer evaluations of diagnostic yield when combining sural nerve biopsy with vastus 
lateralis  muscle biopsy. In 33 patients described as part  of a cohort selected for the 
presence of muscle vasculitis (principally gastrocnemius), vasculitis was not found in 
the sural nerve in 20% of cases.13 Claussen et al described a series of 115 combined sural 
nerve and muscle biopsies (principally tibialis anterior and gastrocnemius) performed 
for suspected vasculitis. Histopathological evidence of vasculitis was found in 39% of 
cases and in agreement with our own findings, combined muscle biopsy did not improve 
diagnostic yield (there were no cases where vasculitis was demonstrated in muscle but 
not in nerve).22 
In contrast with a number of previous studies, we only found a small increase in 
diagnostic yield when performing combined nerve and muscle biopsy. Only one patient 
had evidence of probable vasculitis present in muscle but not in nerve. 
There are potentially a number of reasons why we found only a small increase in 
the diagnostic yield from combined nerve and muscle biopsies in our study. In the vast 
majority of cases we have biopsied a proximal muscle (vastus lateralis) while most other 
groups have biopsied more distal muscles, such as either the PBM or gastrocnemius. 
There could be a distal predominance for muscle vasculitis. In our series, 46% of the 
muscle biopsies from patients with peripheral nerve vasculitis showed vasculitis. This is 
much lower  than  the figure  of  80% using PBM described by Said and colleagues,4 
although two other groups have found results which vary between 31% and 59%.9 , 12 A 
second possibility is the physical proximity of the SPN and PBM versus the remoteness 
of  the sural  nerve and vastus lateralis.  It  is  possible  that  a contiguous muscle to an 
affected nerve is more likely to demonstrate vasculitis than a remote muscle, although 
this has not been studied. These differences may relate to the different nerves being 
biopsied. The sensitivity of SPN/PBM biopsy for vasculitis has been estimated at 60–
70%12 ,  18 and the sensitivity of sural nerve biopsy is given as 50%.7  ,  23  However, it is 
difficult  to  draw  conclusions  given  the  different  patient  groups  and  definitions  of 
vasculitis used in these studies. One study of NSVN patients did compare the sensitivity 
of SPN/PBM versus sural nerve biopsy in the diagnosis of definite vasculitis and found 
increased  sensitivity  of  58% versus  47%,  respectively,  but  this  was  not  statistically 
significant.6 A recent study comparing complications following SPN/PBM versus sural 
nerve biopsy has shown that although SPN biopsy can lead to a greater area of sensory 
loss  compared  with  sural  nerve  biopsy,  there  is  very  little  difference  in  other 
complications.24 
Differences  in  the  published  diagnostic  yield  of  combined  nerve  and  muscle 
biopsy may also relate to the case cohort (eg, the proportion of SVN versus NSVN 
cases) and the stringency of the criteria used to define vasculitis in peripheral nerve and 
muscle. 
CONCLUSION
In  our study  there was a preponderence of females over males.  The clinical 
features were more severe in older age group than younger age group.  Asymmetric 
sensorimotor  neuropathy was the most common clinical presentation. There were no 
casae of pure motor neuropathy. There was a preponderence of SVN over NSVN. In 
SVN  there was a shorter duration between symptoms and nerve biopsy .The routine 
practice of  performing of sural nerve and vasus lateralis biopsy does not significantly 
increase the diagnostic yield of vasculitic neuropathy. 
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